Literature DB >> 2966905

Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.

P Falardeau1, P J Bédard, T Di Paolo.   

Abstract

The relationship between dopamine (DA), dihydroxyphenylacetic acid (DOPAC) or homovanillic acid (HVA) concentrations and [3H]spiperone binding to D2 DA receptors in caudate nucleus, putamen and nucleus accumbens following DAergic lesion with MPTP in monkeys was investigated. The level of DA depletion varied from 37% to 100% while a mean elevation in [3H]spiperone binding density of 114.8 +/- 4.7% of control (P less than 0.01) was observed when DA depletion was at least 90% of control values. A logarithmic correlation (y = -7.19 In x +111.15; r = -0.54, P less than 0.01) between DA concentrations (x) and the density of [3H]spiperone binding sites (y) was observed in all brain regions. The correlation between DOPAC or HVA concentrations and [3H]spiperone binding was best represented by linear rather than logarithmic equations. These results indicate that supersensitivity of DA receptors develops after MPTP lesion in monkeys when the number of remaining nerve fibers becomes too few to compensate for the DA loss.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966905     DOI: 10.1016/0304-3940(88)90575-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons.

Authors:  R D Todd; J Carl; S Harmon; K L O'Malley; J S Perlmutter
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

Review 2.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

3.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

4.  Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with [¹⁸F]fallypride.

Authors:  Marta G Vučković; Quanzheng Li; Beth Fisher; Angelo Nacca; Richard M Leahy; John P Walsh; Jogesh Mukherjee; Celia Williams; Michael W Jakowec; Giselle M Petzinger
Journal:  Mov Disord       Date:  2010-12-15       Impact factor: 10.338

5.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

6.  2-Hydroxyestradiol enhances binge onset in female rats and reduces prefrontal cortical dopamine in male rats.

Authors:  R K Babbs; E L Unger; R L W Corwin
Journal:  Horm Behav       Date:  2012-10-29       Impact factor: 3.587

Review 7.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 8.  Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.

Authors:  Lior Greenbaum; Bernard Lerer
Journal:  Front Neurol       Date:  2015-02-20       Impact factor: 4.003

9.  Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease.

Authors:  Lior Greenbaum; Mordechai Lorberboym; Eldad Melamed; Amihai Rigbi; Yael Barhum; Yoav Kohn; Alexander Khlebtovsky; Bernard Lerer; Ruth Djaldetti
Journal:  Front Neurosci       Date:  2013-04-15       Impact factor: 4.677

10.  [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease.

Authors:  Adam J Stark; Christopher T Smith; Kalen J Petersen; Paula Trujillo; Nelleke C van Wouwe; Manus J Donahue; Robert M Kessler; Ariel Y Deutch; David H Zald; Daniel O Claassen
Journal:  Neuroimage Clin       Date:  2018-02-10       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.